What is Eikon Therapeutics, Inc. 's investing cash flow?

Eikon Therapeutics, Inc. (EIKN) reported investing cash flow of -$203.22M in Q1 2026.

What does investing cash flow mean?

Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

MYR GroupMYRG

-$15.18M-39.4%

Travel + LeisureTNL

-$18M+18.2%

Cabot CorporationCBT

-$109M-55.7%

UnifirstUNF

-$39.45M-32.5%

HES

Hess MidstreamHESM

-$28.8M+36.7%

Alkami Technology, Inc.ALKT

-$4.22M+98.9%

Operating income-$87.3M-22.3%

Net income-$83.0M-21.6%

EPS (diluted)-$2.46+90.9%

Cash & equivalents$161.2M-21.2%

Total debt$254.8M—

Total equity$550.7M+186%

Total assets$850.8M—

Operating cash flow-$89.8M-64.7%

CapEx$262.0K-98.8%

Free cash flow-$90.1M-17.1%

Market cap$514.86M—

Reported directly by Eikon Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Eikon Therapeutics, Inc. ’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Eikon Therapeutics, Inc. 's investing cash flow?: Eikon Therapeutics, Inc. (EIKN) reported investing cash flow of -$203.22M in Q1 2026.
What does investing cash flow mean?: Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.